BUY Ipca Laboratories

Key investor debates beginning to settle

Pharmaceuticals ▸ Result Update ▸ **August 17, 2026**

CMP (Rs): 1,734 | TP (Rs): 1,950

Ipca posted a broad-based sales beat across markets (ex-branded exports) in 1QFY27, with the strong sales beat translating into a 20%/24% EBITDA beat vs our/street estimates. Given the strong 1Q performance, the management has raised its FY27 consolidated topline growth and margin guidance to 14-16% (vs 12-13% earlier) and 23% (vs 22% earlier), respectively. In our view, Ipca's 1QFY27 performance settles key ongoing investor debates around the name: 1) Unichem potentially achieving margins in line with other US generic businesses (mid-teens) in the medium term (for context, the ~11% margin posted by Unichem in 1Q was what we were building in for FY28); 2) room for Ipca's standalone margins to expand further (26.3% ex-forex gain in 1QFY27 vs 25.2% in FY26; path to 30% standalone margin in the medium term, per the management); and 3) scope for a meaningful uptick in Ipca's own US portfolio, given concerns that the opportunity size for some of its products could have shrunk over the years (the robust 1Q US growth for Unichem being primarily driven by Ipca's own portfolio comprehensively addresses this concern, in our view). Note that Ipca's 13% domestic formulations growth in 1Q (full-year guidance also at 12-13%) should be seen in the context of its double-digit domestic growth not being contingent on a recovery in the broader market (structural domestic volume growth well ahead of peers' on 4-year CAGR basis). We raise FY27E/28E EPS by 5%/3% (still below Ipca's revised guidance). We roll forward to Sep-28E EPS and assign a higher target multiple to Unichem. We retain BUY; TP now stands revised up by 8.3% to Rs1,950.

Strong generics + API performance; domestic sales marginally ahead

Domestic formulations growth (13% yoy) was marginally ahead, driven by double-digit growth across key therapies (pain, cardiac, anti-diabetic, CNS, derma, and urology). Branded sales (16% yoy) missed our estimates while generics growth (27% yoy) was meaningfully ahead of expectations, aided by growth across markets (EU, US, and UK; new launch-driven). The sharp increase in generic institutional sales in 1Q was driven by shipments worth ~Rs400mn being delayed from Mar-to-Apr '26. The beat in consolidated EBITDA margin (24%; ~300bps ahead) was primarily driven by operating leverage gains.

KTAs from the earnings call

1) Retains guidance of 10% topline growth and 13% EBITDA margin for Unichem in FY27. 2) Unichem's US business posted 27% growth in 1Q, with Unichem's own US portfolio growing 9%. Expects 7-8 new launches per year in the US (Ipca + Unichem) and 15-17% US growth in the medium term. 3) Expects full-year generic institutional sales to track the Rs2.6-3bn range. 4) Despite fluctuations in input prices and escalating logistics costs, expects sales growth to outpace the increase in raw material costs going forward; margin guidance bakes in the increase in logistics costs. (Additional KTAs on next page)

Target Price – 12M	Sep-27
Change in TP (%)	**8.3**
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	12.5

Stock Data	**IPCA IN**
52-week High (Rs)	1,945
52-week Low (Rs)	1,252
Shares outstanding (mn)	253.7
Market-cap (Rs bn)	440
Market-cap (USD mn)	4,609
Net-debt, FY27E (Rs mn)	(11,464.5)
ADTV-3M (mn shares)	0.3
ADTV-3M (Rs mn)	574.1
ADTV-3M (USD mn)	6.0
Free float (%)	55.3
Nifty-50	24,366.0
INR/USD	95.4

Shareholding,Jun-26	
Promoters (%)	44.7
FPIs/MFs (%)	10.7/37.4

Price Performance

(%)	**1M**	**3M**	**12M**
Absolute	(5.8)	9.5	27.0
Rel. to Nifty	(7.0)	6.4	28.3

1-Year share price trend (Rs)



Ipca Laboratories: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	**FY25**	**FY26**	**FY27E**	**FY28E**	**FY29E**
Revenue	89,396	96,463	107,441	117,637	128,967
EBITDA	17,261	19,786	23,535	26,833	30,578
Adj. PAT	9,427	11,675	13,870	15,906	18,310
Adj. EPS (Rs)	37.2	46.0	54.7	62.7	72.2
EBITDA margin (%)	19.3	20.5	21.9	22.8	23.7
EBITDA growth (%)	30.7	14.6	18.9	14.0	14.0
Adj. EPS growth (%)	43.9	23.8	18.8	14.7	15.1
RoE (%)	14.2	15.6	16.0	15.9	15.8
RoIC (%)	13.1	15.4	17.1	18.2	19.5
P/E (x)	46.7	37.7	31.7	27.7	24.0
EV/EBITDA (x)	25.8	22.5	18.9	16.6	14.6
P/B (x)	6.3	5.5	4.7	4.1	3.6
FCFF yield (%)	2.1	0.6	1.6	2.1	2.5

Source: Company, Emkay Research

Shashank Krishnakumar
shashank.krishnakumar@emkayglobal.com
+91-22-66242466

Mohd Suheb Alam
suheb.alam@emkayglobal.com
+91-22-66242413

Additional KTAs from the earnings call

1) Domestic acute performance was partly impacted by a 24% decline in anti-malarials and flattish sales in anti-bacterials in 1Q; share of anti-malarials in domestic sales is now insignificant (~1%).

2) Ipca's generic business growth (ex-institutional) in 1Q was driven by a strong growth in Europe (~70%) and an 8% increase in US shipments (marginal decline in Canada).

3) Unichem's topline growth was aided by growth in other markets—Brazil (52%; now profitable) and RoW (2x)—as well as in the API business (73%). Europe sales grew 3%.

4) Unichem remains focused on API cost reduction with the process of API source change to Ipca currently underway.

5) Expects Unichem's revenue and margin profile to improve with new product registrations in various international markets, including Europe, Australia, New Zealand, Canada, and Chile. Ipca is yet to start leveraging Unichem's portfolio in ex-US markets.

6) The India field-force stands at ~7,000 MRs; expects addition of ~200 MRs in the middle of the current financial year, with the launch of new divisions.

7) Biosimilar pipeline: 7 candidates with engineering batches taken for 2 products; known titer values are 2x or more vs current market values; pipeline includes one high-value product, which is expected to be launched around patent expiry; expects stability results and initiation of clinical trials (in line with the protocols for global agencies) in FY28.

8) Capex guidance of Rs7-8bn for FY27; focus areas for capacity addition: extended-release formulations in Pithampur, biosimilar manufacturing (Rs1bn more on pilot facilities and R&D), API capacity in Dewas, and intermediates (continuous processes) at Wardha.

9) Expects term loan outstanding of Rs700mn by the end of FY27 (Rs1.9bn currently; no working capital debt) and a decline in interest costs.

Exhibit 1: Ipca Laboratories – 1QFY27 earnings snapshot

Ipca - P&L	1QFY26	1QFY27A	yoy chg	1QFY27E	Delta vs Emkay	1QFY27E (consensus)	Delta vs consensus	4QFY26	qoq chg
(Rs mn)									
Net sales	**23,089**	**27,881**	**21%**	**26,372**	**6%**	**25,847**	**8%**	**23,885**	**17%**
Raw material	6,916	7,974	15%	7,674	4%			6,916	15%
Gross Profit	**16,173**	**19,908**	**23%**	**18,698**	**6%**			**16,969**	**17%**
- Margin	**70.0%**	**71.4%**	**135 bps**	**70.9%**	**50 bps**			**71.0%**	**36 bps**
Staff costs	5,432	6,016	11%	5,881	2%			5,330	13%
Other expenses	6,577	7,197	9%	7,252	-1%			6,800	6%
EBITDA	**4,164**	**6,695**	**61%**	**5,564**	**20%**	**5,420**	**24%**	**4,839**	**38%**
- EBITDA Margin	**18.0%**	**24.0%**	**598 bps**	**21.1%**	**291 bps**	**21.0%**	**304 bps**	**20.3%**	**375 bps**
Other income	327	253	-23%	303	-17%			337	-25%
Finance costs	185	119	-36%	152	-22%			202	-41%
Depreciation	1,001	1,108	11%	1,134	-2%			1,071	3%
Exceptional items	-	-		-				142	
Profit Before Tax (PBT)	3,305	5,721	73%	4,582	25%			4,045	41%
Tax	961	1,493	55%	1,191	25%			951	57%
- Tax rate	29.1%	26.1%		26.0%				23.5%	
Minority + Associates	(12)	(209)		(113)				(103)	
Reported PAT	**2,332**	**4,019**	**72%**	**3,277**	**23%**			**2,991**	**34%**
Adj PAT	**2,332**	**4,019**	**72%**	**3,277**	**23%**	**3,154**	**27%**	**2,849**	**41%**
Adj EPS (Rs)	**9.2**	**15.8**	**72%**	**12.9**	**23%**			**11.2**	**41%**

% Cost Ratios	1QFY26	1QFY27A	% yoy	1QFY27E	Delta vs Emkay	4QFY26	qoq chg
Raw Material cost	30.0	28.6	-135 bps	29.1	-50 bps	29.0	36 bps
Staff cost	23.5	21.6	-195 bps	22.3	-72 bps	22.3	74 bps
Mfg & Other expenses	28.5	25.8	-267 bps	27.5	-169 bps	28.5	266 bps

Sales Break-up	1QFY26	1QFY27A	% yoy	1QFY27E	Delta vs Emkay	4QFY26	qoq chg
Domestic	**10,372**	**11,735**	**13%**	**11,533**	**2%**	**9,577**	**23%**
Formulations	9,610	10,821	13%	10,619	2%	8,533	27%
API	762	914	20%	914	0%	1,043	-12%
Exports	**6,998**	**9,354**	**34%**	**8,431**	**11%**	**8,455**	**11%**
Formulations	4,496	6,030	34%	5,680	6%	6,053	0%
- Generic	2,682	3,400	27%	3,165	7%	3,410	0%
- Branded	1,236	1,433	16%	1,792	-20%	1,902	-25%
- Institutional	578	1,198	107%	723	66%	741	62%
Subsidiaries	5,620	6,689	19%	6,294	6%	5,741	16%
API	2,502	3,324	33%	2,752	21%	2,402	38%

Source: Company, Bloomberg, Emkay Research

Exhibit 2: Changes to estimates

Rs mn	FY27E			FY28E			FY29E		
	Old	New	Change	Old	New	Change	Old	New	Change
Promotional biz - branded	7,234	6,637	-8%	7,885	7,234	-8%	8,595	7,885	-8%
Generic - Institutional tenders	2,996	3,009	0%	3,236	3,235	0%	3,495	3,478	0%
Europe and others	12,696	13,616	7%	14,030	14,909	6%	15,503	16,326	5%
Export formulations - Total	**22,926**	**23,262**	**1%**	**25,150**	**25,378**	**1%**	**27,675**	**27,771**	**0%**
Export API	11,097	11,777	6%	11,762	12,366	5%	12,468	12,984	4%
Total Exports	**34,023**	**35,039**	**3%**	**36,913**	**37,744**	**2%**	**40,143**	**40,756**	**2%**
Domestic formulations	42,371	42,677	1%	47,032	47,457	1%	52,206	52,772	1%
Domestic API	3,698	3,698	0%	3,920	3,920	0%	4,155	4,155	0%
Total Domestic	**46,070**	**46,375**	**1%**	**50,952**	**51,377**	**1%**	**56,361**	**56,927**	**1%**
Other operating revenue	453	453	0%	498	498	0%	548	548	0%
Unichem	24,006	24,299	1%	26,017	26,497	2%	28,204	28,900	2%
Revenue from Other Subsidiaries	1,200	1,274	6%	1,345	1,520	13%	1,523	1,836	21%
Total income	**105,751**	**107,441**	**2%**	**115,726**	**117,637**	**2%**	**126,780**	**128,967**	**2%**
Raw Material/FG	30,774	30,997	1%	33,329	33,585	1%	36,132	36,433	1%
%	29.1%	28.9%		28.8%	28.6%		28.5%	28.3%	
Gross Profit	**74,977**	**76,444**	**2%**	**82,397**	**84,052**	**2%**	**90,647**	**92,534**	**2%**
Gross Profit margin	70.9%	71.2%		71.2%	71.5%		71.5%	71.8%	
EBITDA	**22,496**	**23,535**	**5%**	**25,723**	**26,833**	**4%**	**29,384**	**30,578**	**4%**
EBITDA margin	21.3%	21.9%		22.2%	22.8%		23.2%	23.7%	
PAT	13,248	13,870	5%	15,508	15,906	3%	18,115	18,310	1%
PAT margin	12.5%	12.9%		13.4%	13.5%		14.3%	14.2%	
EPS (Rs)	**52.2**	**54.7**	**5%**	**61.1**	**62.7**	**3%**	**71.4**	**72.2**	**1%**

Source: Emkay Research

Ipca Laboratories: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	**89,396**	**96,463**	**107,441**	**117,637**	**128,967**
Revenue growth (%)	16.0	7.9	11.4	9.5	9.6
EBITDA	**17,261**	**19,786**	**23,535**	**26,833**	**30,578**
EBITDA growth (%)	30.7	14.6	18.9	14.0	14.0
Depreciation & Amortization	3,978	4,181	4,576	4,970	5,403
EBIT	**13,283**	**15,604**	**18,958**	**21,862**	**25,175**
EBIT growth (%)	37.8	17.5	21.5	15.3	15.2
Other operating income	-	-	-	-	-
Other income	928	1,144	1,119	1,218	1,475
Financial expense	849	759	437	340	243
PBT	**13,362**	**15,989**	**19,640**	**22,741**	**26,407**
Extraordinary items	(2,051)	(264)	0	0	0
Taxes	3,436	3,812	5,106	5,913	6,866
Minority interest	(476)	(427)	(670)	(928)	(1,237)
Income from JV/Associates	(23)	(76)	7	7	7
Reported PAT	**7,377**	**11,411**	**13,870**	**15,906**	**18,310**
PAT growth (%)	34.8	54.7	21.5	14.7	15.1
Adjusted PAT	**9,427**	**11,675**	**13,870**	**15,906**	**18,310**
Diluted EPS (Rs)	**37.2**	**46.0**	**54.7**	**62.7**	**72.2**
Diluted EPS growth (%)	43.9	23.8	18.8	14.7	15.1
DPS (Rs)	**4.0**	**2.1**	**5.5**	**6.3**	**7.2**
Dividend payout (%)	**10.8**	**4.5**	**10.0**	**10.0**	**10.0**
EBITDA margin (%)	19.3	20.5	21.9	22.8	23.7
EBIT margin (%)	14.9	16.2	17.6	18.6	19.5
Effective tax rate (%)	25.7	23.8	26.0	26.0	26.0
NOPLAT (pre-IndAS)	**9,867**	**11,885**	**14,029**	**16,178**	**18,629**
Shares outstanding (mn)	254	254	254	254	254

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	254	254	254	254	254
Reserves & Surplus	69,231	80,384	92,867	107,183	123,662
Net worth	**69,485**	**80,638**	**93,121**	**107,437**	**123,916**
Minority interests	14,398	14,603	15,273	16,201	17,438
Non-current liab. & prov.	2,781	2,243	2,243	2,243	2,243
Total debt	**13,017**	**7,039**	**3,439**	**2,339**	**1,239**
Total liabilities & equity	**101,260**	**106,555**	**116,194**	**130,432**	**147,151**
Net tangible fixed assets	38,505	41,803	44,256	46,957	49,937
Net intangible assets	2,032	1,976	1,877	1,771	1,659
Net ROU assets	2,184	2,603	2,602	2,625	2,672
Capital WIP	6,162	7,616	7,616	7,616	7,616
Goodwill	906	828	828	828	828
Investments [JV/Associates]	1,910	1,836	1,836	1,836	1,836
Cash & equivalents	**11,076**	**11,980**	**14,904**	**22,462**	**31,769**
Current assets (ex-cash)	51,609	51,789	57,173	62,190	67,738
Current Liab. & Prov.	16,176	16,942	17,964	18,919	19,970
NWC (ex-cash)	**35,433**	**34,847**	**39,209**	**43,272**	**47,768**
Total assets	**101,260**	**106,555**	**116,195**	**130,432**	**147,151**
Net debt	1,941	(4,941)	(11,465)	(20,123)	(30,530)
Capital employed	101,260	106,555	116,194	130,432	147,151
Invested capital	**75,970**	**78,625**	**85,342**	**91,999**	**99,364**
BVPS (Rs)	273.9	317.8	367.0	423.5	488.4
Net Debt/Equity (x)	-	(0.1)	(0.1)	(0.2)	(0.2)
Net Debt/EBITDA (x)	0.1	(0.2)	(0.5)	(0.7)	(1.0)
Interest coverage (x)	16.7	22.1	46.0	67.9	109.5
RoCE (%)	**15.1**	**16.8**	**18.8**	**19.4**	**19.8**

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
PBT (ex-other income)	12,411	14,769	18,528	21,529	24,938
Others (non-cash items)	3,842	(4,200)	0	0	0
Taxes paid	(3,613)	(4,140)	(5,106)	(5,913)	(6,866)
Change in NWC	(4,255)	49	(4,362)	(4,062)	(4,496)
Operating cash flow	**13,213**	**11,420**	**14,072**	**16,864**	**19,223**
Capital expenditure	(3,876)	(8,877)	(6,931)	(7,565)	(8,271)
Acquisition of business	(340)	74	0	0	0
Interest & dividend income	-	-	-	-	-
Investing cash flow	**(8,695)**	**(2,468)**	**(5,543)**	**(6,075)**	**(6,521)**
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(858)	(5,978)	(3,600)	(1,100)	(1,100)
Payment of lease liabilities	80	19	87	71	55
Interest paid	(849)	(759)	(437)	(340)	(243)
Dividend paid (incl tax)	(1,015)	(524)	(1,387)	(1,591)	(1,831)
Others	(187)	(293)	(269)	(272)	(275)
Financing cash flow	**(2,830)**	**(7,535)**	**(5,606)**	**(3,231)**	**(3,395)**
Net chg in Cash	1,688	1,417	2,924	7,558	9,307
OCF	13,213	11,420	14,072	16,864	19,223
Adj. OCF (w/o NWC chg.)	17,468	11,371	18,435	20,927	23,719
FCFF	9,337	2,543	7,142	9,299	10,952
FCFE	8,487	1,784	6,705	8,959	10,708
OCF/EBITDA (%)	76.5	57.7	59.8	62.8	62.9
FCFE/PAT (%)	115.1	15.6	48.3	56.3	58.5
FCFF/NOPLAT (%)	**94.6**	**21.4**	**50.9**	**57.5**	**58.8**

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	46.7	37.7	31.7	27.7	24.0
P/CE(x)	32.8	27.7	23.9	21.1	18.6
P/B (x)	6.3	5.5	4.7	4.1	3.6
EV/Sales (x)	5.0	4.6	4.1	3.8	3.5
EV/EBITDA (x)	25.8	22.5	18.9	16.6	14.6
EV/EBIT(x)	33.5	28.5	23.5	20.4	17.7
EV/IC (x)	5.9	5.7	5.2	4.8	4.5
FCFF yield (%)	2.1	0.6	1.6	2.1	2.5
FCFE yield (%)	1.9	0.4	1.5	2.0	2.4
Dividend yield (%)	0.2	0.1	0.3	0.4	0.4
DuPont-RoE split					
Net profit margin (%)	10.5	12.1	12.9	13.5	14.2
Total asset turnover (x)	0.9	1.0	1.0	1.0	0.9
Assets/Equity (x)	1.4	1.4	1.3	1.2	1.2
RoE (%)	**14.2**	**15.6**	**16.0**	**15.9**	**15.8**
DuPont-RoIC					
NOPLAT margin (%)	11.0	12.3	13.1	13.8	14.4
IC turnover (x)	1.2	1.2	1.3	1.3	1.3
RoIC (%)	**13.1**	**15.4**	**17.1**	**18.2**	**19.5**
Operating metrics					
Core NWC days	144.7	131.9	133.2	134.3	135.2
Total NWC days	**144.7**	**131.9**	**133.2**	**134.3**	**135.2**
Fixed asset turnover	2.1	2.3	2.4	2.5	2.6
Opex-to-revenue (%)	49.6	50.2	49.2	48.6	48.0

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
02-Jun-26	1,508	1,800	Buy	Shashank Krishnakumar
17-Feb-26	1,492	1,700	Buy	Shashank Krishnakumar
03-Dec-25	1,444	1,700	Buy	Shashank Krishnakumar

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

[1] An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

[2] Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 17, 2026
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 17, 2026
5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 17, 2026
6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.
CIN - L67120MH1995PLC084899
7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

Seshadri Kumar Sen

Digitally signed by Seshadri Kumar Sen
Date: 2026.08.17 00:24:28 +05'30'